Back to Search

JACQUELINE KARP, MD

MD

Internal Medicine Physician

NPI: 1306006887Individual

Specialties, Licenses & Credentials

Student in an Organized Health Care Education/Training Program

Student in an Organized Health Care Education/Training Program

Code: 390200000X

Internal Medicine PhysicianPrimary

Internal Medicine

Code: 207R00000X

D79798(MD)

Research & Publications (20)

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
PMID 19109557·Blood·2009
3-trial
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
PMID 18483374·Clin Cancer Res·2008
3-trial
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
PMID 17640728·Leuk Res·2008
3-trial
Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.
PMID 17882662·Cancer Invest·2007
6-review
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
PMID 17671131·Clin Cancer Res·2007
3-trial
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.
PMID 17562873·Blood·2007
3-trial
Trying to improve clinical outcome in AML: lessons from negative trials.
PMID 15863196·Leuk Res·2005
8-other
Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.
PMID 16556050·Future Oncol·2005
6-review
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
PMID 16322302·Clin Cancer Res·2005
3-trial
Targeting the process of farynesylation for therapy of hematologic malignancies.
PMID 16305490·Curr Mol Med·2005
6-review

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
4940 EASTERN AVE
BALTIMORE, MD 21224

Quick Facts

NPI
1306006887
Entity Type
Individual
Gender
Female
Medicare
Not confirmed
Specialties
2
Locations
1
Publications
20

Are you this provider?

Claim Your Profile